BMO Capital analyst Evan Seigerman notes that a U.S. district court issued a ruling in favor of Acadia Pharmaceuticals (ACAD) in their Nuplazid patent infringement lawsuit with Aurobindo, confirming today that Aurobindo infringed on claims 4 and 5 of Acadia’s 11,452,721 U.S. formulation patent. Today’s announcement likely extends the lifespan of pimavanserin and could extend the company’s patent protection from 2030 to 2038, removing a “key overhang,” says the analyst, who reiterates an Outperform rating and $24 price target on Acadia shares.
Kens
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$17.55 |
Change
0.540(3.17%) |
Mkt cap ! $2.211B | |||
| Open | High | Low | Value | Volume |
| $17.48 | $18.44 | $17.40 | $16.43M | 922.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 2624 | $17.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.70 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 07/08/2025 (20 minute delay) ? |
| NEU (ASX) Chart |